Utah Medical Products, Inc. (UTMD) Stock

About Utah Medical Products, Inc.

Utah Medical Products, Inc. is led by CEO Kevin L. Cornwell, employs 155 people, headquartered in US, publicly traded since 1999.

Utah Medical Products, Inc. (UTMD) stock trades at $74.23 with a market capitalization of $235.59M. The stock is valued at a price-to-earnings (P/E) ratio of 22.60, price-to-book of 1.93, price-to-sales of 6.54. Over the past 52 weeks the stock has ranged between $53.66 and $76.89, and currently trades 3.5% below its 52-week high. It pays a dividend yielding 1.67%.

On profitability, Utah Medical Products, Inc. generates a return on equity (ROE) of 8.74%, return on capital employed of 8.39%, an operating margin of 28.21%, a net profit margin of 29.04%.

Utah Medical Products, Inc. by the numbers, 2016–2025

Between 2016 and 2025 Utah Medical Products, Inc. reported revenue of $39.0M rising to $39.0M, a change of 0.0% across 10 years. Compounded, revenue has grown -1.5% a year over five years, -9.1% over three, -4.9% over the last twelve months. Net profit fell to $11.0M.

Operating margin went from 41.2% in 2016 to 29.6% in 2025, a fall of 11.6 percentage points. The most recent net margin is 29.04%. On a trailing twelve-month basis to Jun '26, revenue is $37.0M and net profit $12.0M.

Borrowings stand at $0, cash from operations was $15.0M in the latest year, positive in 10 of the last 10.

Return on equity has averaged 12.5% over five years, and was 9.2% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Utah Medical Products, Inc. (UTMD) — frequently asked questions